Avadel Pharmaceuticals PLC AVDL:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/16/22 EDT
4.07quote price arrow up+0.27 (+7.11%)
Volume
664,456
52 week range
3.49 - 11.59
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.07
  • 52 Week High11.59
  • 52 Week High Date11/15/21
  • 52 Week Low3.49
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap240.29M
  • Shares Out59.04M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-49.63

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.07
  • 52 Week High11.59
  • 52 Week High Date11/15/21
  • 52 Week Low3.49
  • 52 Week Low Date05/12/22
  • Market Cap240.29M
  • Shares Out59.04M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-49.63

RATIOS/PROFITABILITY

  • EPS (TTM)-1.54
  • P/E (TTM)-2.64
  • Fwd P/E (NTM)-2.42
  • EBITDA (TTM)-98.505M
  • ROE (TTM)-94.21%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)67.45%
  • Net Margin (TTM)-55.02%
  • Debt To Equity (MRQ)258.38%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Avadel Pharmaceuticals PLC

There is no recent news for this security.

Profile

MORE
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in...
Geoffrey Glass
Non-Executive Independent Chairman of the Board
Gregory Divis Jr.
Chief Executive Officer, Chief Operating Officer, Executive Vice President, Director
Thomas McHugh
Chief Financial Officer
Address
Block 10-1 Blanchardstown Corporate Park
Ballycoolin
Dublin
15
Ireland

Top Peers

SYMBOLLASTCHG%CHG
CRMD
CorMedix Inc
3.61+0.34+10.40%
SCPH
scPharmaceuticals Inc
4.69+0.25+5.63%
OCUL
Ocular Therapeutix Inc
3.36+0.08+2.44%
GTBP
GT Biopharma Inc
2.06+0.13+6.74%
SEEL
Seelos Therapeutics Inc
0.5562-0.0073-1.2955%